Effectiveness, safety and tolerability of a complex homeopathic medicinal product in the prevention of recurrent acute upper respiratory tract infections in children: a multicenter, open, comparative, randomized, controlled clinical trial

Table 2 Descriptive statistics and relative risk of treatment related effects on acute URTI frequencies

Post-treatment period	Treatment group	Number of acute URTIs experienced			Relative risk (RR)
Post-treatment period	Treatment group	Mean ± SD	Median (P25 %, P75 %)	Min-Max	Estimate (Lower -Upper 95 %-CI)	p
Months 1–3 of post-treatment	CalSuli-4-02	1.1 ± 1.0	1.0 (0.0, 2.0)	0.0–5.0	0.84 (0.67–1.05)	0.1185
Months 1–3 of post-treatment	Control	1.3 ± 0.9	1.0 (1.0, 2.0)	0.0–4.0	0.84 (0.67–1.05)	0.1185
Months 4–6 of post-treatment	CalSuli-4-02	1.1 ± 0.9	1.0 (0.0, 2.0)	0.0–4.0	0.89 (0.71–1.10)	0.2857
Months 4–6 of post-treatment	Control	1.2 ± 0.9	1.0 (0.0, 2.0)	0.0–3.0	0.89 (0.71–1.10)	0.2857
Full 6 months of post-treatment	CalSuli-4-02	2.2 ± 1.6	2.0 (1.0, 3.0)	0.0–7.0	0.86 (0.72–1.03)	0.1099
Full 6 months of post-treatment	Control	2.5 ± 1.4	2.0 (1.0, 4.0)	0.0–6.0	0.86 (0.72–1.03)	0.1099

CI confidence interval, RR relative risk (i.e. the estimated risk of experiencing an event in children treated with CalSuli-4-02 divided by the estimated risk of experiencing an event in children treated with the comparator homeopathic product as obtained from Poisson regression model), SD standard deviation, URTIs upper respiratory tract infections, ITT intention-to-treat analysis

ISSN: 2049-6958